| Literature DB >> 28059670 |
Pryscilla Fanini Wowk1, Luís Henrique Franco1, Denise Morais da Fonseca1, Marina Oliveira Paula1, Élcio Dos Santos Oliveira Vianna2, Ana Paula Wendling3, Valéria Maria Augusto4, Silvana Maria Elói-Santos4, Andréa Teixeira-Carvalho3, Flávia Dias Coelho Silva5, Solange Alves Vinhas5, Olindo Assis Martins-Filho3, Moisés Palaci5, Célio Lopes Silva1, Vânia Luiza Deperon Bonato1.
Abstract
Previously we showed that 65-kDa Mycobacterium leprae heat shock protein (Hsp65) is a target for the development of a tuberculosis vaccine. Here we evaluated peripheral blood mononuclear cells (PBMC) from healthy individuals or tuberculosis patients stimulated with two forms of Hsp65 antigen, recombinant DNA that encodes Hsp65 (DNA-HSP65) or recombinant Hsp65 protein (rHsp65) in attempting to mimic a prophylactic or therapeutic study in vitro, respectively. Proliferation and cytokine-producing CD4+ or CD8+ cell were assessed by flow cytometry. The CD4+ cell proliferation from healthy individuals was stimulated by DNA-HSP65 and rHsp65, while CD8+ cell proliferation from healthy individuals or tuberculosis patients was stimulated by rHSP65. DNA-HSP65 did not improve the frequency of IFN-gamma+ cells from healthy individuals or tuberculosis patients. Furthermore, we found an increase in the frequency of IL-10-producing cells in both groups. These findings show that Hsp65 antigen activates human lymphocytes and plays an immune regulatory role that should be addressed as an additional antigen for the development of antigen-combined therapies.Entities:
Keywords: IFN-γ; IL-10; tuberculosis; vaccine
Mesh:
Substances:
Year: 2017 PMID: 28059670 PMCID: PMC5443371 DOI: 10.1080/21645515.2016.1264547
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452